{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:58:13Z","timestamp":1759366693228,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":2300,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Medical Microbiology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.4103\/0255-0857.148827","type":"journal-article","created":{"date-parts":[[2015,1,7]],"date-time":"2015-01-07T04:30:00Z","timestamp":1420605000000},"page":"S20-S25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S1","title":["The predictive value of early indicators for HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with Telbivudine treatment for 104 weeks"],"prefix":"10.1016","volume":"33","author":[{"given":"Juan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-yao","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"En-qiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4103\/0255-0857.148827_bib1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"EASL Clinical Practice Guidelines: Management of chronic hepatitis B","volume":"50","year":"2009","journal-title":"J Hepatol"},{"key":"10.4103\/0255-0857.148827_bib2","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.2165\/11319850-000000000-00000","article-title":"Predictors of treatment response in chronic hepatitis B","volume":"69","author":"Wong","year":"2009","journal-title":"Drugs"},{"key":"10.4103\/0255-0857.148827_bib3","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s12072-008-9083-0","article-title":"The Roadmap concept: Using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B","volume":"2","author":"Gane","year":"2008","journal-title":"Hepatol Int"},{"key":"10.4103\/0255-0857.148827_bib4","first-page":"1021a","article-title":"Baseline and early on-treatment characteristics in patients with chronic hepatitis B infection achieving an early on-treatment response to peginterferon alfa-2a: Interim results from the rgt study","volume":"54","author":"Hou","year":"2011","journal-title":"Hepatology"},{"key":"10.4103\/0255-0857.148827_bib5","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.3748\/wjg.v16.i32.4095","article-title":"Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels","volume":"16","author":"Lv","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.4103\/0255-0857.148827_bib6","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.3748\/wjg.v13.i30.4085","article-title":"Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine","volume":"13","author":"Chae","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.4103\/0255-0857.148827_bib7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12072-009-9143-0","article-title":"On-treatment monitoring of HBV DNA levels: Predicting response and resistance to oral antiviral therapy at week 24 versus week 48","volume":"3","author":"Chang","year":"2009","journal-title":"Hepatol Int"},{"key":"10.4103\/0255-0857.148827_bib8","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.22744","article-title":"Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients","volume":"49","author":"Moucari","year":"2009","journal-title":"Hepatology"},{"key":"10.4103\/0255-0857.148827_bib9","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/jmv.22089","article-title":"Correlation of serum hepatitis B surface antigen level with response to entecavir in naive patients with chronic hepatitis B","volume":"83","author":"Lee","year":"2011","journal-title":"J Med Virol"},{"key":"10.4103\/0255-0857.148827_bib10","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1111\/j.1365-2893.2010.01423.x","article-title":"An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg-positive patients","volume":"18","author":"Zhang","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.4103\/0255-0857.148827_bib11","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1111\/j.1365-2893.2011.01473.x","article-title":"Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients","volume":"18","author":"Gramenzi","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.4103\/0255-0857.148827_bib12","article-title":"Time-dependent relative risk of hepatocellular carcinoma (HCC for markers of chronic hepatitis B: The REVEAL-HBV study","volume":"42","author":"Chen","year":"2005","journal-title":"Hepatology"},{"key":"10.4103\/0255-0857.148827_bib13","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1478-3231.2010.02267.x","article-title":"Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B","volume":"30","author":"Croagh","year":"2010","journal-title":"Liver Int"},{"key":"10.4103\/0255-0857.148827_bib14","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/j.1478-3231.2005.01182.x","article-title":"APASL Abstracts, Bali 2005","volume":"25","year":"2005","journal-title":"Liver Int"},{"key":"10.4103\/0255-0857.148827_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000334076","article-title":"Hepatitis B virus serology to predict antiviral response in chronic hepatitis B","volume":"84","author":"Kim","year":"2011","journal-title":"Digestion"},{"key":"10.4103\/0255-0857.148827_bib16","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s12072-010-9227-x","article-title":"Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation","volume":"5","author":"Peng","year":"2010","journal-title":"Hepatol Int"},{"key":"10.4103\/0255-0857.148827_bib17","article-title":"Telbivudine globe trial at year two: Efficacy, safety, and predictors of outcome in patients with chronic hepatitis B","volume":"132","author":"Han","year":"2007","journal-title":"Gastroenterology"},{"key":"10.4103\/0255-0857.148827_bib18","doi-asserted-by":"crossref","first-page":"S9-S","DOI":"10.1016\/S0168-8278(09)60019-2","article-title":"Kinetics of Hbsag decline in HBeAg plus chronic hepatitis b patients with 3 years of telbivudine treatment during the globe study","volume":"50","author":"Wursthorn","year":"2009","journal-title":"J Hepatol"},{"key":"10.4103\/0255-0857.148827_bib19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1872-034X.2009.00592.x","article-title":"Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-alpha-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B","volume":"40","author":"Tangkijvanich","year":"2010","journal-title":"Hepatol Res"},{"key":"10.4103\/0255-0857.148827_bib20","first-page":"1257","article-title":"Serum HBV DNA level at week 24 as a proper predictor for the effect of 2-year lamivudine treatment","volume":"124","author":"Zheng","year":"2011","journal-title":"Chin Med J"},{"key":"10.4103\/0255-0857.148827_bib21","first-page":"681a","article-title":"Baseline parameters predict both early virologic response and longer term outcomes for telbivudine-treated patients with chronic hepatitis B (the GLOBE study)","volume":"46","author":"Zeuzem","year":"2007","journal-title":"Hepatology"},{"key":"10.4103\/0255-0857.148827_bib22","first-page":"A766-A","article-title":"Resistance determination in patients experiencing virologic breakthrough following telbivudine or lamivudine therapy in the international globe trial","volume":"132","author":"Standring","year":"2007","journal-title":"Gastroenterology"},{"key":"10.4103\/0255-0857.148827_bib23","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2036.2011.04973.x","article-title":"Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B","volume":"35","author":"Peng","year":"2012","journal-title":"Aliment Pharm Ther"}],"container-title":["Indian Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085721000670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085721000670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T19:15:27Z","timestamp":1759346127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0255085721000670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":23,"alternative-id":["S0255085721000670"],"URL":"https:\/\/doi.org\/10.4103\/0255-0857.148827","relation":{},"ISSN":["0255-0857"],"issn-type":[{"type":"print","value":"0255-0857"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The predictive value of early indicators for HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with Telbivudine treatment for 104 weeks","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Medical Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4103\/0255-0857.148827","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Indian Journal of Medical Microbiology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}